Docoh
Loading...

74 results

Filter options loading...
Top filers
Top filing types
Recent filing years
424B5
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Prospectus supplement for primary offering
4:46pm
believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial needs … believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial
S-3
PCSA Processa Pharmaceuticals Inc
30 Jun 21
Shelf registration
4:02pm
, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks
8-K
EX-99.1
PCSA Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
-molecule product candidates – Nyxol and APX3330 – targeting front and back of the eye indications in late-stage trials. As part of its strategy, Ocuphire
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
that such action, suit or proceeding has been instituted, and, thereafter, the Parties shall meet as soon as possible to discuss the overall strategy
8-K
EX-99.1
PCSA Processa Pharmaceuticals Inc
13 May 21
Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
5:28pm
, including expressed or implied statements regarding future results of operations and financial position, business strategy, product candidates
10-Q
2021 Q1
PCSA Processa Pharmaceuticals Inc
13 May 21
Quarterly report
4:30pm
Strategy Our strategy is to acquire or in-license development candidates that will not only treat a specific group of patients with unmet medical needs
DEF 14A
PCSA Processa Pharmaceuticals Inc
22 Apr 21
Definitive proxy
2:00pm
in public company governance and strategy. Geraldine Liu Pannu – Ms. Pannu has served as a Director since February 13, 2020. Ms. Pannu has over 25 years … strategy. Director Independence The Nasdaq Marketplace Rules require a majority of a listed company’s Board of Directors to be comprised
424B3
PCSA Processa Pharmaceuticals Inc
12 Apr 21
Prospectus supplement
1:44pm
our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward
10-K/A
2020 FY
PCSA Processa Pharmaceuticals Inc
7 Apr 21
Annual report (amended)
4:23pm
of the competitive landscape and professional and personal experiences and expertise relevant to our growth strategy. The following table provides information … Chief Administrative Officer Patrick Lin Chief Business and Strategy Officer James Stanker Chief Financial Officer Non-Employee Directors: Dr. Khalid
S-3
PCSA Processa Pharmaceuticals Inc
1 Apr 21
Shelf registration
8:00pm
of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements are subject … of development. Our Strategy Our strategy is to acquire or in-license development candidates that will not only treat a specific group of patients
10-Q
2020 Q3
PCSA Processa Pharmaceuticals Inc
12 Nov 20
Quarterly report
4:01pm
criteria. Our Strategy Our vision is to develop drugs with potentially high return on investment and lower risk of development failure. Our portfolio drugs … strategy to achieve our vision include: identifying drugs that have potential efficacy in patients with an unmet medical need, as demonstrated by some
8-K
PCSA Processa Pharmaceuticals Inc
5 Nov 20
Processa Pharmaceuticals Announces the Appointment of
9:00am
will continue in his role as Chief Business Strategy Officer. Item 9.01. Financial Statements and Exhibits. Exhibit No. Description Press Release
8-K
EX-99.1
PCSA Processa Pharmaceuticals Inc
13 Oct 20
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
9:30am
Lin, our Chief Business- Strategy Officer, to ensure that our existing investors and potential investors are informed as the Processa drugs hit
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
(PCS12852, PCS6422, PCS11T and PCS100) and will begin developing these products once adequate funding has been obtained. Our Strategy Our vision … a greater chance for approval in a population of patients who need treatment options. The key pillars of our strategy to achieve our vision include
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
and PCS100) and will begin developing these products once adequate funding has been obtained. Our Strategy Our vision is to develop drugs with potentially … in a population of patients who need treatment options. The key pillars of our strategy to achieve our vision include: identifying drugs that have
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
developing these products once adequate funding has been obtained. Our Strategy Our vision is to develop drugs with potentially high return on investment … of patients who need treatment options. The key pillars of our strategy to achieve our vision include: identifying drugs that have potential efficacy
S-1/A
PCSA Processa Pharmaceuticals Inc
17 Jul 20
IPO registration (amended)
5:25pm
of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements are subject … in a population of patients who need treatment options. Part of our business strategy is: to identify drugs that have potential efficacy in patients
8-K
EX-99.2
PCSA Processa Pharmaceuticals Inc
1 Jun 20
Entry into a Material Definitive Agreement
7:01am
when on ATT-11T compared to irinotecan. “The licensing of this product from Aposense fits with our strategy to continue to bring innovative products
DEF 14C
PCSA Processa Pharmaceuticals Inc
27 May 20
Information statement
5:15pm
limitation, changes in our business strategy or planned capital expenditures, or to reflect the occurrence of unanticipated events. VOTE REQUIRED